Atea Pharmaceuticals announces first patient dosed in SUNRISE-3 Phase 3 trial

Atea Pharmaceuticals announced the enrollment of the first patient in the SUNRISE-3 Phase 3 trial, a global multicenter trial evaluating bemnifosbuvir for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression to hospitalization and death. The patient was enrolled and dosed at a U.S. clinical trial site. The study is designed to enroll at least 1,500 patients with mild or moderate COVID-19, and the primary endpoint is all-cause hospitalization or death through Day 29 in at least 1,300 patients in the monotherapy arm. "Our COVID-19 strategy for bemnifosbuvir is to focus on the highest unmet medical need. Our goal is to deliver a safe, effective and convenient treatment option for people that remain vulnerable to hospitalization or death due to the limitations of current antiviral treatments and the ability of the virus to evade vaccines and monoclonal antibodies," said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals. "New variants not susceptible to currently available preventive tools are driving COVID-19 infection waves, which should enable timely patient enrollment in SUNRISE-3."